Increasing both the number of shares and share price, iTeos Therapeutics has raised more than $201m in an offering that provided an exit to 6 Dimensions Capital.

US-based immuno-oncology drug developer iTeos Therapeutics raised more than $201m in a listing on Friday that offered an exit to 6 Dimensions Capital, the investment firm co-founded by pharmaceutical company WuXi AppTec.

The company priced its shares at $19, above its previous target of $18, and upped the number of shares by approximately 350,000 to 10.58 million. It has listed on the Nasdaq Global Market using the ticker symbol ITOS.

Spun out of Université catholique de Louvain (UCL) and Ludwig…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn